pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Verzenio
drug
save

abemaciclib

Marketedupdated 6mo ago
by Eli Lilly and Co
Approved
annual revenue · 2024–2024peak $5.2B
2024: $5.2B2024$5.2B
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying abemaciclib

  • phase2A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancernot yet recruitingn=120
  • phase1A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancerrecruitingn=242
  • phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancerrecruitingn=788
  • phase3Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutationrecruitingn=600
  • EP1(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Canceractive not recruitingn=20
  • phase2A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancerrecruitingn=285
  • phase2A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumorsactive not recruitingn=55
  • phase2A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)recruitingn=43

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 28, 2031
~4.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Sep 28, 2031compositionUS 78552114.9y
  • Sep 28, 2031compositionUS 78552114.9y
  • Sep 28, 2031compositionUS 78552114.9y
  • Sep 28, 2031compositionUS 78552114.9y

News(7)

  • An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
    biopharma_dive · 1mo ago
  • AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
    SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.
    biospace · 2mo ago
  • AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
    The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…
    biospace · 2mo ago
  • FDA Grants Accelerated Approval to a New Breast Cancer Treatment
    The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…
    fda_press · 2mo ago
  • RallyBio tries again for reverse merger, this time with Avenzo
    It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
    biopharma_dive · 5mo ago
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    endpoints · 5mo ago
  • Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
    Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
    onclive · 6mo ago
brand
Verzenio
generic
abemaciclib
indication
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
phase
marketed
approved
2017-09-28
Data sources
openFDA · ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?